Dr. Veneris is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215Phone+1 617-632-5269
Education & Training
University of ChicagoResidency, Internal Medicine, 2012 - 2014
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2012
Certifications & Licensure
MA State Medical License 2018 - 2025
NH State Medical License 2024 - 2024
IL State Medical License 2014 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 4 citationsPhase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.Ryan B Corcoran, Khanh T Do, Jeong E Kim, James M Cleary, Aparna R Parikh
Clinical Cancer Research. 2024-05-01 - 14 citationsSafety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown
Clinical Cancer Research. 2023-11-14 - 21 citationsAntitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.Thierry André, Dominique Berton, Giuseppe Curigliano, Renaud Sabatier, Anna V Tinker
JAMA Network Open. 2023-11-01
Press Mentions
- Clinical Trial: Mirvetuximab Soravtansine and Pembrolizumab in Endometrial CancerOctober 26th, 2020
SGO Issues May 18, 2017May 18th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
